Grape Seed Extract
Polyphenol extract that modestly trims blood pressure and lipids.
What is Grape Seed Extract?
Grape Seed Extract (Vitis vinifera) is a heart and metabolic supplement used for lower blood pressure. NutriDex grades the human evidence as Moderate. Grape seed extract is a polyphenol concentrate rich in proanthocyanidins, marketed for heart and metabolic health. Meta-analyses of randomized trials show real but modest effects: pooled systolic BP falls roughly 1.5–6 mmHg and diastolic about 2–3 mmHg, with the largest benefit in younger, obese, or metabolic-syndrome subjects. Supplementation also lowers LDL-cholesterol (~0.17 mmol/L) and triglycerides (~0.11 mmol/L) and modestly reduces fasting glucose and C-reactive protein, though HDL, HbA1c and body weight are usually unchanged, and flow-mediated dilation does not reliably improve. Smaller trials suggest benefit in non-alcoholic fatty liver disease and in slowing hard exudates in early diabetic retinopathy. Limitations are real: trials are short, doses and extract standardization vary widely, some are industry-linked, and no study has measured cardiovascular events. It is a reasonable adjunct, not a substitute for proven therapy.
Purported Benefits
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Lower blood pressureMeta-analyses show systolic falls ~1.5-6 mmHg; one meta-analysis found no systolic effect, so consistency is imperfect. | Moderate | ↑ benefit · small | 2 |
| Reduce LDL and triglyceridesDose-response meta-analysis: LDL down ~0.17 mmol/L, triglycerides ~0.11 mmol/L; HDL and total cholesterol unchanged. | Moderate | ↑ benefit · small | 2 |
| Improve fasting glucoseMeta-analysis found significant fasting glucose drop but no change in HbA1c; short trials only. | Moderate | ↑ benefit · small | 1 |
| Reduce inflammation (CRP)Single meta-analysis reported lower CRP; antioxidant claims otherwise rest on mechanism, not hard outcomes. | Preliminary | ↑ benefit · small | 1 |
| Slow early diabetic retinopathyOne 1-year RCT improved hard-exudate severity vs placebo; single trial, needs replication. | Preliminary | ↑ benefit · moderate | 1 |
| Improve NAFLD markersSingle 8-week RCT lowered HOMA-IR, transaminases and steatosis; one small trial only. | Preliminary | ↑ benefit · moderate | 1 |
| Improve endothelial function (FMD)Meta-analysis found flow-mediated dilation did not reliably improve. | Preliminary | — no effect · negligible | 1 |